Related Experiment Videos
Liposomes and lipid carriers in the treatment of microbial infections
I A Bakker-Woudenberg1, A F Lokerse
1Department of Clinical Microbiology, Erasmus University Rotterdam, The Netherlands.
Abstract:
Since antibiotic treatment of severe infections is not always successful, intensification of the antibiotic treatment is needed. Targeting of antibiotics to infected tissues or cells by encapsulation in liposomes is under investigation and may be of importance in the treatment of infections that prove refractory to conventional forms of antibiotic therapy. In animal models of intracellular infections involving the mononuclear phagocyte system--parasitic, fungal, bacterial and viral infections--an improved therapeutic index and reduced toxicity resulting from encapsulation of the antibiotics in liposomes have been demonstrated. By varying the lipid composition of the liposomes it is possible to manipulate their intracellular degradation and thereby the intracellular release and therapeutic availability of the antibiotic. Efficacy of liposome-encapsulated antibiotics in the treatment of infectious diseases outside the mononuclear phagocyte system may be realized by manipulation of the liposome composition. Evidence for this is found in the treatment of systemic fungal infections, in which liposome appear to be very effective as a carrier of amphotericin B. The most advanced application of liposome-based therapy is in this field, and clinical studies with liposome-encapsulated amphotericin B have been in progress for several years.
Insights
Liposome encapsulation enhances antibiotic delivery for severe infections, improving treatment outcomes and reducing toxicity. This targeted approach is crucial for infections resistant to conventional therapies.
Area of Science:
- Pharmacology
- Drug Delivery Systems
- Infectious Diseases
Background:
- Conventional antibiotic treatments for severe infections are not always successful.
- Targeting antibiotics to infected tissues via liposomes is a promising strategy for refractory infections.
- Liposome encapsulation offers potential for improved therapeutic index and reduced toxicity.
Purpose of the Study:
- To investigate the efficacy of liposome-encapsulated antibiotics for treating severe and refractory infections.
- To explore the manipulation of liposome composition for optimized intracellular drug release and therapeutic availability.
- To evaluate the potential of liposome-based antibiotic delivery beyond the mononuclear phagocyte system.
Main Methods:
- Encapsulation of antibiotics within liposomes.
- Utilizing animal models of intracellular infections (parasitic, fungal, bacterial, viral).
- Varying liposome lipid composition to control intracellular degradation and drug release.
- Investigating efficacy in systemic fungal infections using liposome-encapsulated amphotericin B.
Main Results:
- Demonstrated improved therapeutic index and reduced toxicity in animal models of intracellular infections.
- Showcased the ability to manipulate intracellular antibiotic release by altering liposome composition.
- Indicated potential efficacy for infections outside the mononuclear phagocyte system.
- Highlighted liposomes as effective carriers for amphotericin B in systemic fungal infections.
Conclusions:
- Liposome encapsulation represents a significant advancement in antibiotic delivery for severe infections.
- Tailoring liposome composition allows for optimized drug release and therapeutic efficacy.
- Liposome-based antibiotic therapy shows particular promise for systemic fungal infections, with ongoing clinical studies.